Table 3. Incidence of patients with persistent anti-therapeutic antibody response, following ADC administration in Phase 1.
| Drug | Incidence | Effect on PK |
|---|---|---|
| Brentuximab vedotin | 2/39 (5%) | Reduced exposure |
| AVE9633 | 1/54 (2%) | Not reported |
| huC242-DM1 | 0/37 (0%) | None |
| Trastuzumab emtansine | 1/22 (5%) | None |
| MLN2704 | 0/23 (0%) | None |
| PSMA ADC | 0/53 (0%) | None |
| SAR3419 | 1/39 (3%) | None |